Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for G75228109 since 12/18/2024, largest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Research Alliance Holdings IV LLC
13D
|
17.0% |
7/21/2026
Event 7/14/2026
|
|
| Research Alliance Holdings IV LLC | 17.0% | ||
| Matthew Hammond | 17.0% | ||
|
Perceptive Advisors LLC
13G
|
7.7% |
7/20/2026
Event 7/13/2026
|
|
| Perceptive Advisors LLC | 7.7% | ||
| Joseph Edelman | 7.7% | ||
| Perceptive Life Sciences Master Fund, Ltd. | 7.7% | ||
|
Biotechnology Value Fund L P
13G
|
6.4% |
7/20/2026
Event 7/13/2026
|
|
| Biotechnology Value Fund L P | 3.4% | ||
| BVF I GP LLC | 3.4% | ||
| Biotechnology Value Fund II LP | 2.5% | ||
| BVF II GP LLC | 2.5% | ||
| Biotechnology Value Trading Fund OS LP | 0.4% | ||
| BVF Partners OS Ltd. | 0.4% | ||
| BVF GP Holdings LLC | 5.9% | ||
| BVF Partners L P/IL | 6.4% | ||
| BVF Inc/IL | 6.4% | ||
| Lampert Mark N | 6.4% | ||
|
Commodore Capital LP
13G
|
5.5% |
7/20/2026
Event 7/13/2026
|
|
| Commodore Capital LP | 5.5% | ||
| Commodore Capital Master LP | 5.5% | ||
| Robert Egen Atkinson | 5.5% | ||
| Michael Kramarz | 5.5% | ||
|
Trails Edge Capital Partners, LP
13G
|
5.5% |
7/21/2026
Event 7/14/2026
|
|
| Trails Edge Capital Partners, LP | 5.5% | ||
| Trails Edge Biotechnology Master Fund, LP | 5.5% | ||
| Ortav Yehudai | 5.5% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|